Tommaso Schirinzi

List of Publications by Year
in descending order

93	2,227	236612 25	276539 41
papers	citations	h-index	g-index

95	95	95	3310
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Adult-onset sporadic chorea: real-world data from a single-centre retrospective study. Neurological Sciences, 2022, 43, 387-392.	0.9	6
2	Serum Substance <scp>P</scp> Is Increased in Parkinson's Disease and Correlates with Motor Impairment. Movement Disorders, 2022, 37, 228-230.	2.2	7
3	Upper Body Physical Rehabilitation for Children with Ataxia through IMU-Based Exergame. Journal of Clinical Medicine, 2022, 11, 1065.	1.0	7
4	Tau and Amyloid-Î² Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters. Frontiers in Neurology, 2022, 13, 748599.	1.1	8
5	Using a Video Device and a Deep Learning-Based Pose Estimator to Assess Gait Impairment in Neurodegenerative Related Disorders: A Pilot Study. Applied Sciences (Switzerland), 2022, 12, 4642.	1.3	7
6	The Nrf2 induction prevents ferroptosis in Friedreich's Ataxia. Redox Biology, 2021, 38, 101791.	3.9	78
7	COVID-19: dealing with a potential risk factor for chronic neurological disorders. Journal of Neurology, 2021, 268, 1171-1178.	1.8	50
8	How Comorbidity Reflects on Cerebrospinal Fluid Biomarkers of Neurodegeneration in Aging. Journal of Alzheimer's Disease Reports, 2021, 5, 87-92.	1.2	1
9	Friedreich ataxia in COVID-19 time: current impact and future possibilities. Cerebellum and Ataxias, 2021, 8, 4.	1.9	8
10	Increase of Prokineticinâ€2 in Serum of Patients with Parkinson's Disease. Movement Disorders, 2021, 36, 1031-1033.	2.2	15
11	Design of an Innovative Methodology for Cerebrospinal Fluid Analysis: Preliminary Results. Sensors, 2021, 21, 3767.	2.1	4
12	Working memory, attention and planning abilities in NKX2.1-related chorea. Parkinsonism and Related Disorders, 2021, 88, 24-27.	1.1	1
13	Effects of head trauma and sport participation in young-onset Parkinsonâ€™s disease. Journal of Neural Transmission, 2021, 128, 1185-1193.	1.4	11
14	Biofluids profile of Î±-Klotho in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2021, 90, 62-64.	1.1	8
15	Neuroimaging findings in leukoencephalopathy with calcifications and cysts: case report and review of the literature. Neurological Sciences, 2021, 42, 4471-4487.	0.9	1
16	Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinsonâ€™s disease cohort. Npj Parkinson's Disease, 2021, 7, 82.	2.5	10
17	Spinal vascular lesions: anatomy, imaging techniques and treatment. European Journal of Radiology Open, 2021, 8, 100369.	0.7	6
18	Movement disorders in primary central nervous system lymphoma: two unreported cases and a review of literature. Neurological Sciences, 2021, 42, 905-910.	0.9	2

#	Article	IF	Citations
19	What substance P might tell us about the prognosis and mechanism of Parkinson's disease?. Neuroscience and Biobehavioral Reviews, 2021, 131, 899-911.	2.9	5
20	Technology-Based Objective Measures Detect Subclinical Axial Signs in Untreated, de novo Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 113-122.	1.5	25
21	Speech and Language Disorders in Friedreich Ataxia: Highlights on Phenomenology, Assessment, and Therapy. Cerebellum, 2020, 19, 126-130.	1.4	12
22	Systemic Activation of Nrf2 Pathway in Parkinson's Disease. Movement Disorders, 2020, 35, 180-184.	2.2	66
23	Development of SaraHome: A novel, well-accepted, technology-based assessment tool for patients with ataxia. Computer Methods and Programs in Biomedicine, 2020, 188, 105257.	2.6	21
24	Clinical course of paroxysmal dyskinesias throughout pregnancy. Parkinsonism and Related Disorders, 2020, 80, 19-20.	1.1	5
25	A Dual Centre Study of Pain in Parkinsonâ€™s Disease and Its Relationship with Other Non-Motor Symptoms. Journal of Parkinson's Disease, 2020, 10, 1817-1825.	1.5	17
26	Validation of low-cost system for gait assessment in children with ataxia. Computer Methods and Programs in Biomedicine, 2020, 196, 105705.	2.6	17
27	Physical Activity Changes and Correlate Effects in Patients with Parkinson's Disease during <scp>COVID</scp>â€19 Lockdown. Movement Disorders Clinical Practice, 2020, 7, 797-802.	0.8	53
28	Movement disorders in ADAR1 disease: Insights from a comprehensive cohort. Parkinsonism and Related Disorders, 2020, 79, 100-104.	1.1	6
29	Self-reported needs of patients with Parkinsonâ€™s disease during COVID-19 emergency in Italy. Neurological Sciences, 2020, 41, 1373-1375.	0.9	59
30	Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features. Neurobiology of Aging, 2020, 90, 119-124.	1.5	41
31	Amyloid-Î²42/Neurogranin Ratio as a Potential Index for Cognitive Impairment in Parkinsonâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 1171-1178.	1.2	11
32	A wearable video-oculography based evaluation of saccades and respective clinical correlates in patients with early onset ataxia. Journal of Neuroscience Methods, 2020, 338, 108697.	1.3	3
33	Ischemic injury precipitates neuronal vulnerability in Parkinson's disease: Insights from PINK1 mouse model study and clinical retrospective data. Parkinsonism and Related Disorders, 2020, 74, 57-63.	1.1	16
34	The continuum between neurodegeneration, brain plasticity, and movement: a critical appraisal. Reviews in the Neurosciences, 2020, 31, 723-742.	1.4	30
35	Long-term treatment with rotigotine in drug-naÃ¯ve PSP patients. Acta Neurologica Belgica, 2019, 119, 113-116.	0.5	3
36	Dystonia-Ataxia with early handwriting deterioration in COQ8A mutation carriers: A case series and literature review. Parkinsonism and Related Disorders, 2019, 68, 8-16.	1.1	25

#	Article	IF	Citations
37	Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay. Frontiers in Neuroscience, 2019, 13, 889.	1.4	25
38	Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinsonâ€™s disease. Nature Communications, 2019, 10, 3945.	5.8	127
39	The effect of postural deformities on back function and pain in patients with Parkinsonâ€™s disease. NeuroRehabilitation, 2019, 44, 419-424.	0.5	12
40	Response to Jardim and colleagues regarding comments on â€˜Natural history of a cohort of <scp>ABCD</scp>1 variant female carriersâ€™. European Journal of Neurology, 2019, 26, e77.	1.7	0
41	Dietary Vitamin E as a Protective Factor for Parkinson's Disease: Clinical and Experimental Evidence. Frontiers in Neurology, 2019, 10, 148.	1.1	89
42	Association between physical activity and dementiaâ€™s risk factors in patients with Parkinsonâ€™s disease. Journal of Neural Transmission, 2019, 126, 319-325.	1.4	26
43	The influence of postural deformities on neck function and pain in patients with Parkinsonâ€™s disease. NeuroRehabilitation, 2019, 44, 79-84.	0.5	10
44	One-year outcome of coenzyme Q10 supplementation in ADCK3 ataxia (ARCA2). Cerebellum and Ataxias, 2019, 6, 15.	1.9	15
45	Involvement of the Chemokine Prokineticin-2 (PROK2) in Alzheimerâ€™s Disease: From Animal Models to the Human Pathology. Cells, 2019, 8, 1430.	1.8	17
46	SLC2A1 mutations are a rare cause of pediatric-onset hereditary spastic paraplegia. European Journal of Paediatric Neurology, 2019, 23, 329-332.	0.7	11
47	Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. Parkinsonism and Related Disorders, 2019, 61, 19-25.	1.1	64
48	CSF Î±-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients. Parkinsonism and Related Disorders, 2019, 61, 203-206.	1.1	30
49	Natural history of a cohort of <scp>ABCD</scp>1 variant female carriers. European Journal of Neurology, 2019, 26, 326-332.	1.7	19
50	Novel Homozygous KCNJ10 Mutation in a Patient with Non-syndromic Early-Onset Cerebellar Ataxia. Cerebellum, 2018, 17, 499-503.	1.4	10
51	ATP1A3 -related epileptic encephalopathy responding to ketogenic diet. Brain and Development, 2018, 40, 433-438.	0.6	23
52	Serum uric acid in Friedreich Ataxia. Clinical Biochemistry, 2018, 54, 139-141.	0.8	7
53	Dopaminergic involvement in a drummer with focal dystonia: A case study. Clinical Neurology and Neurosurgery, 2018, 166, 54-55.	0.6	2
54	Childhood Rapid-Onset Ataxia: Expanding the Phenotypic Spectrum of ATP1A3 Mutations. Cerebellum, 2018, 17, 489-493.	1.4	24

#	Article	IF	Citations
55	Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. Journal of Neural Transmission, 2018, 125, 673-679.	1.4	31
56	Does Pisa syndrome affect upper limb function in patients with Parkinsonâ€™s disease? An observational cross-sectional study. NeuroRehabilitation, 2018, 42, 143-148.	0.5	10
57	Promising rodent models in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 46, S10-S14.	1.1	9
58	Longitudinal gait assessment in a stiff person syndrome. International Journal of Rehabilitation Research, 2018, 41, 377-379.	0.7	6
59	Non-invasive Focal Mechanical Vibrations Delivered by Wearable Devices: An Open-Label Pilot Study in Childhood Ataxia. Frontiers in Neurology, 2018, 9, 849.	1.1	10
60	Pisa Syndrome in Parkinsonâ€™s Disease: Evidence for Bilateral Vestibulospinal Dysfunction. Parkinson's Disease, 2018, 2018, 1-6.	0.6	6
61	Effectiveness of robot-assisted gait training on motor impairments in people with Parkinsonâ€™s disease: a systematic review and meta-analysis. International Journal of Rehabilitation Research, 2018, 41, 287-296.	0.7	34
62	Spread of dystonia in patients with idiopathic adultâ€onset laryngeal dystonia. European Journal of Neurology, 2018, 25, 1341-1344.	1.7	11
63	Centrality of Early Synaptopathy in Parkinsonâ€™s Disease. Frontiers in Neurology, 2018, 9, 103.	1.1	41
64	Amyloid-Mediated Cholinergic Dysfunction in Motor Impairment Related to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, 525-532.	1.2	59
65	Dystonia as a network disorder: a concept in evolution. Current Opinion in Neurology, 2018, 31, 498-503.	1.8	57
66	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. Journal of Neural Transmission, 2018, 125, 1373-1379.	1.4	25
67	Impaired intracortical transmission in G2019S leucine richâ€repeat kinase Parkinson patients. Movement Disorders, 2017, 32, 750-756.	2.2	16
68	Assessment of serum uric acid as risk factor for tauopathies. Journal of Neural Transmission, 2017, 124, 1105-1108.	1.4	16
69	Rotigotine may control drooling in patients with Parkinsonâ€™s Disease: Preliminary findings. Clinical Neurology and Neurosurgery, 2017, 156, 63-65.	0.6	10
70	Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimerâ€™s disease. Journal of Neural Transmission, 2017, 124, 1621-1625.	1.4	27
71	Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreichâ€™s Ataxia. International Journal of Molecular Sciences, 2017, 18, 2173.	1.8	58
72	Assessment of Hearing Impairment in Parkinson's Disease: Implications for Differential Diagnosis and Disease Progression. , 2017, 07, .		4

#	Article	IF	Citations
73	Outlining a Population â€œat Riskâ€•of Parkinsonâ€™s Disease: Evidence from a Case-Control Study. Parkinson's Disease, 2016, 2016, 1-7.	0.6	3
74	Early synaptic dysfunction in Parkinson's disease: Insights from animal models. Movement Disorders, 2016, 31, 802-813.	2.2	127
75	Mild cerebello-thalamo-cortical impairment in patients with normal dopaminergic scans (SWEDD). Parkinsonism and Related Disorders, 2016, 28, 23-28.	1.1	20
76	Transient MR-angiography changes associated with morphological alterations in epileptic seizure: A short case series. Journal of the Neurological Sciences, 2016, 360, 25-29.	0.3	2
77	Occurrence of Writing Tremor in Patients With Scans Without Evidence of Dopaminergic Deficit. Movement Disorders Clinical Practice, 2016, 3, 421-424.	0.8	2
78	Dopamine-dependent CB1 receptor dysfunction at corticostriatal synapses in homozygous PINK1 knockout mice. Neuropharmacology, 2016, 101, 460-470.	2.0	12
79	Exposure to low-dose rotenone precipitates synaptic plasticity alterations in PINK1 heterozygous knockout mice. Neurobiology of Disease, 2016, 91, 21-36.	2.1	36
80	Double hit mouse model of Parkinson's disease. Oncotarget, 2016, 7, 80109-80110.	0.8	6
81	A Clinical and Biochemical Analysis in the Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus. Frontiers in Neurology, 2015, 6, 86.	1.1	39
82	Symptomatic nonconvulsive status epilepticus erroneously suggestive of sporadic Creutzfeldtâ€“Jakob disease. Journal of the Neurological Sciences, 2015, 348, 274-276.	0.3	9
83	Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinsonâ€™s disease patients with chronic pain. Journal of Neurology, 2015, 262, 2164-2170.	1.8	35
84	Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia. Neuropharmacology, 2014, 85, 440-450.	2.0	33
85	Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia. Neurobiology of Disease, 2014, 65, 124-132.	2.1	69
86	PINK1 heterozygous mutations induce subtle alterations in dopamineâ€dependent synaptic plasticity. Movement Disorders, 2014, 29, 41-53.	2.2	40
87	CSF biomarkers in superficial siderosis: a new tool for diagnosis and evaluation of therapeutic efficacy of deferiproneâ€”a case report. Neurological Sciences, 2014, 35, 1151-1152.	0.9	7
88	Transient parkinsonism after unilateral midbrain stroke: a compensatory intervention from the healthy side?. Neurological Sciences, 2014, 35, 2013-2015.	0.9	6
89	Aberrant striatal synaptic plasticity in monogenic parkinsonisms. Neuroscience, 2012, 211, 126-135.	1.1	18
90	How relevant is the cholinergic system in DYT1 dystonia?. Basal Ganglia, 2012, 2, 227-230.	0.3	0

#	Article	IF	Citations
91	Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic transmission. Neuropharmacology, 2011, 61, 632-637.	2.0	36
92	Altered profile and D2-dopamine receptor modulation of high voltage-activated calcium current in striatal medium spiny neurons from animal models of Parkinson's disease. Neuroscience, 2011, 177, 240-251.	1.1	15
93	Centrality of Striatal Cholinergic Transmission in Basal Ganglia Function. Frontiers in Neuroanatomy, 2011, 5, 6.	0.9	113